Akèy › Lukemi lenfositè kwonik › Pennsylvania › Pittsburgh
Etid klinik pou Lukemi lenfositè kwonik nan Pittsburgh, PA
10 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Pittsburgh (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Ap rekriteFaz 3
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Ap rekriteFaz 3
- West Penn Hospital, Pittsburgh
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Ap rekriteFaz 1/2
- Research Site, Pittsburgh
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center, Pittsburgh
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Ap rekriteFaz 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Ap rekriteFaz 2
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Cincinnati, OH14 etid
Lòt etid nan Pittsburgh
- Kansè Poumon ki pa ti selil48 etid
- Kansè (tout kalite)41 etid
- Kansè nan tete39 etid
- Kansè kolorektal32 etid
- Kansè Metastatik31 etid
- Melanom31 etid
- Kansè ovè30 etid
- Kansè Endomèt23 etid
- Kansè poumon23 etid
- Kansè pwostat23 etid
- Akidan serebavaskilè22 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.